Immune Drug Beats Antidepressants, Psilocybin Phase 3 Wins, AI Therapy Trust Drops to 8%, Mindfulness May Increase Bias: 13 Essential Mindfulness & Mental Wellness Stories (May 31, 2026)

Mindfulness and mental wellness made dramatic headlines this week, from a landmark immune-system drug that outperformed standard antidepressants in treatment-resistant depression to back-to-back Phase 3 psilocybin wins that could reshape psychiatry. As mindfulness and mental wellness research accelerates across clinical labs, behavior science departments, and digital health platforms, the week of May 31, 2026 delivered … Read more

MM120’s Phase 3 Anxiety Trial, the 2.5× Gamification Effect & Habit-Stacking’s Mainstream Moment (April 2026)

Wellness news April 2026 is delivering a mix of clinical breakthroughs and behavioral science worth paying attention to — especially if you’re someone who tracks streaks, builds routines, or is curious about what’s actually working in mental health right now. From a psychedelic-derived anxiety drug entering Phase 3 trials, to new evidence that gamified wellness … Read more

Item added to cart.
0 items - $0.00